Novartis (NYSE:NVS) and MSN Pharmaceuticals have reached agreement in a Delaware federal court to dismiss patent litigation ...

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Hailee Steinfeld is teaming up with Novartis to raise awareness about breast cancer with an empowering Super Bowl 59 ...

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...

SALES FORECAST: Novartis's sales are forecast at $12.78 billion, according to analysts' estimates compiled by Visible Alpha. This compares with $11.42 billion the year before. Shares rose 5.1% over ...

As Trump appointee and vaccine skeptic RFK Jr. looks toward Washington, Novartis (NVS) CEO Vas Narasimhan is concerned about ...

In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

In Novartis Pharms. Corp. v. Torrent Pharma Inc., the U. S. Court of Appeals for the Federal Circuit shut down efforts to market a generic version of the heart disease drug ENTRESTO which is sold ...

Novartis Pharmaceuticals Corporation v. Torrent Pharma Inc., No. 23-2218 (Fed. Cir. 2025) — On January 10, 2025, the Federal Circuit reversed ...

The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took ...